Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018–2019 Season

BACKGROUND: The Vaccine Safety Datalink (VSD) identified a statistical signal for an increased risk of Guillain-Barré syndrome (GBS) in days 1–42 after 2018–2019 high-dose influenza vaccine (IIV3-HD) administration. We evaluated the signal using Medicare. METHODS: We conducted early- and end-of-seas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Perez-Vilar, Silvia, Hu, Mao, Weintraub, Eric, Arya, Deepa, Lufkin, Bradley, Myers, Tanya, Woo, Emily Jane, Lo, An-Chi, Chu, Steve, Swarr, Madeline, Liao, Jiemin, Wernecke, Michael, MaCurdy, Tom, Kelman, Jeffrey, Anderson, Steven, Duffy, Jonathan, Forshee, Richard A
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7882024/
https://ncbi.nlm.nih.gov/pubmed/33137184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiaa543
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars